Sildenafil Tablet, Film Coated
Product Images NDC 71335-1005

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71335-1005). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351005)

Label for Sildenafil Citrate 20 mg tablet, film-coated, oral dosage form. The label includes a comparison to Revatio 20 mg tablet by Teva Pharmaceuticals USA. It indicates a package quantity of 10 tablets, storage instructions at room temperature (20°-25°C), a caution to keep drugs out of reach of children, and shows the labeler as Bryant Ranch Prepack, Burbank, CA. The NDC displayed is 71335-1005.*

FDA Label Image

Figure-10 (Sildenafil Fig 10)

A forest plot chart depicting placebo-corrected change in 6-minute walk distance (meters) for Sildenafil 20 mg taken three times daily. The chart compares groups based on baseline walk distance, etiology, PH criteria for functional capacity and therapeutic class, gender, age, mean PAP, and PVRI. Data points with confidence intervals are shown for each subgroup, separated by placebo and Sildenafil treatment.*

FDA Label Image

Figure-11 (Sildenafil Fig 11)

A line graph comparing the percentage of patients without a clinically worsening event over time between Sildenafil and a placebo. The x-axis represents days from randomization (0 to 112 days), and the y-axis shows the percentage (0% to 100%). Two lines depict the treatment groups, with Sildenafil showing a generally higher percentage of patients without worsening events compared to placebo over the study period.*

FDA Label Image

Fig-12 (Sildenafil Fig 12)

A line graph depicting mean change from baseline over 12 weeks for Sildenafil dosing regimens at 1 mg, 5 mg, and 20 mg taken three times daily (TID). The y-axis represents change from baseline in meters, and the x-axis shows study weeks 4, 8, and 12. Error bars indicate standard error for each data point.*

FDA Label Image

Fig-6 (Sildenafil Fig 6)

FDA Label Image

Fig-8 (Sildenafil Fig 8)

A fold change and 90% confidence interval chart depicting the drug interaction effects of various interacting drugs with sildenafil. It shows changes in parameters such as INR AUC, INR Cmax, bleeding time, AUC, and Cmax relative to the interacting drug alone, with corresponding recommendations on dose adjustments, mainly indicating no dose adjustment for most drugs and caution for ritonavir coadministration.*

FDA Label Image

Figure-9 (Sildenafil Fig 9)

A line graph depicting changes from baseline (in meters) over a 12-week study period at weeks 4, 8, and 12. The graph compares four groups: Placebo, Sildenafil 20 mg TID, Sildenafil 40 mg TID, and Sildenafil 80 mg TID, showing the progression of data points and variability for each group across the study timeline.*

FDA Label Image

Figure-7 (Sildenafil Figure 7)

A horizontal dot plot chart showing the fold change with 90% confidence intervals of AUC and Cmax values for various interacting drugs relative to sildenafil alone. The vertical line at x=1 indicates no change. Drugs listed include Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir with recommendations on dose adjustment alongside each drug's data.*

FDA Label Image

Str (Sildenafil Str)

Chemical structure of the active ingredient Sildenafil. The diagram shows the molecular components and arrangement typical for Sildenafil, including heterocyclic rings and various functional groups as depicted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.